Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06865144 · ClinicalTrials.gov registry record · Phase 4
Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT
A Phase 4 study of Primary Open Angle Glaucoma or Ocular Hypertension, sponsored by East Coast Institute for Research.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 70
- Enrollment target
- 1
- Study location
NCT06865144 is a Phase 4 study of Primary Open Angle Glaucoma or Ocular Hypertension that is actively recruiting participants, run by East Coast Institute for Research. The registered enrollment target is 70 participants, above the 41-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (71% higher). The trial reports 1 study location across 1 state.
The verdict
NCT06865144, a Phase 4 study of Primary Open Angle Glaucoma or Ocular Hypertension, is actively recruiting participants, sponsored by East Coast Institute for Research.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 70 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.
Conditions Studied
Interventions
- DRUG Netarsudil ophthalmic solution 0.02%
- DRUG Artificial tears
Study Locations (1)
Florida
- East Coast Institute for Research at Florida Eye Specialists - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2025-06-27 |
| Est. Completion | 2026-04-01 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06865144
The ClinicalTrials.gov registry entry for NCT06865144 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 41-participant average among 3 other Primary Open Angle Glaucoma or Ocular Hypertension trials with a reported enrollment target (71% higher). The listed sponsor is East Coast Institute for Research, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Primary Open Angle Glaucoma or Ocular Hypertension appearing as the primary indexed condition, and to 2 interventions - of which Netarsudil ophthalmic solution 0.02% is the first listed.
NCT06865144 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06865144 about?
NCT06865144 is a clinical study titled "Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT". The purpose of this study is to collect data about how Rhopressa affects IOP in patients who have had an SLT procedure in both eyes.
What is the current status of trial NCT06865144?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 70 participants. The study started on 2025-06-27. Estimated completion is 2026-04-01.
What conditions does trial NCT06865144 study?
This clinical trial studies the following conditions: Primary Open Angle Glaucoma or Ocular Hypertension.
What interventions are being tested in trial NCT06865144?
The interventions under investigation include: Netarsudil ophthalmic solution 0.02% (DRUG), Artificial tears (DRUG).
Who is sponsoring clinical trial NCT06865144?
This trial is sponsored by East Coast Institute for Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06865144 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Primary Open Angle Glaucoma or Ocular Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients
RECRUITING
-
Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension
COMPLETED · Phase 2
-
Study of Netarsudil Ophthalmic Solution in Subjects With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.